Objective:

We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019.

Methods:

The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year.

Results:

The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54–11.60, p = .001) increase per year and there was a mean 11.54% (95% CI 11.03–12.06, p = .001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year.

Conclusion:

The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.

中文翻译：

---

2010-2019 年英格兰初级保健中注意力缺陷多动障碍药物的不良反应报告和处方趋势

客观的：

我们调查了 2010 年至 2019 年间英格兰初级保健中 ADHD 药物的处方趋势和药物不良反应 (ADR)。

方法：

筛选了呈现初级保健处方数据的处方成本分析数据库和呈现每种药物报告的所有疑似 ADR 的交互式药物分析配置文件。使用线性回归分析对数据进行分析，以检查每年的年平均变化。

结果：

为 ADHD 开出的处方药平均每年增加 11.07% (95% CI 10.54–11.60, p  = .001)，平均每年增加 11.54% (95% CI 11.03–12.06, p  = .001)在费用中。ADHD 药物严重和致命 ADR 的总体报告每年减少 1.79%。胍法辛显示每年平均增长 40%。

结论：

英格兰初级保健中多动症药物的使用增加可能是多种因素的结果，例如多动症患病率的增加。